Sensitivity& Specificityof Simultaneous use of RASSF1Agene DNA methylation and FHL1 gene Expression technique in Differential Diagnosis of Benign Tumors from Papillary Carcinoma tumor in Thyroid gland
The aim of this study is determining the sensitivity and specificity of simultaneous use of both DNA methylation of RASSF1A gene and expression of FHL1 gene in the differential diagnosis of benign tumors from malign papillary carcinoma tumor in the thyroid gland.
160 samples of patients with malign thyroid tumors (80 samples) and benign thyroid (80 samples) were used in this study. The RNA was extracted from paraffinic samples, and then cDNA was made from it. Gene expression was investigated by Real Time PCR mixture containing the Cyber Green fluorescence material. After DNA extraction, the hypermethylation of the gene was performed using COBRA method. Finally, an epidemiological calculation was used for calculating the effects of sensitivity and specificity of two simultaneous tests.
There was a negative significant correlation (P ≤0.05) between promoter hypermethylation of the RASSF1A gene and the FHL1 gene expression. Net sensitivity of simultaneous use of the promoter methylation of the RASSF1A gene (quantitative and quantitative) and expression of the FHL1 gene were 98.2% and 79.32%, respectively. The Net specificity of simultaneous use of the promoter methylation of the RASSF1A gene (quantitative and quantitative) and the FHL1 gene expression test were 39.47 and 75.29%, respectively.
simultaneous use of the hypermethylation of the RASSF1A gene promoter as a qualitative and expression test for FHL1 gene is more sensitive and more reliable in differential diagnosis of benign tumors from malign papillary carcinoma tumors.
- حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران میشود.
- پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانههای چاپی و دیجیتال را به کاربر نمیدهد.